Resources
- sort by:
- Relevance
- Date
- Popularity
- Vitro and PhosphoSolutions Collaborate to Study Stem Cell Proteomics
- Vitro Diagnostics, Inc. (OTC BB: VODG), dba Vitro Biopharma, announced establishment of research collaboration with PhosphoSolutions, LLC Aurora Colorado to characterize intracellular signaling mechanisms involved with regulation of stem cell growth and differentiation. Vitro has previously developed 29 adult pancreatic stem cell lines and has developed methodologies to induce...
- Research articles 2006-01-11
- Vitro Signs Letter of Intent to Form Strategic Alliance With European Biotechnology Firm
- Vitro Diagnostics, Inc. (OTC BB: VODG), a biotechnology company, executed a binding letter of intent to form a broad-ranging strategic alliance with BioCare Europe headquartered in Rome, Italy. The partnership includes various agreements with regard to commercialization of Vitro's stem cell lines for use in research and development and...
- Research articles 2005-09-21
- Vitro Establishes US East Coast Operations
- AURORA, Colo. -- Vitro Diagnostics, Inc. (OTCBB: VODG - News), a biotechnology company, announced establishment of east coast operations in central New Jersey. This facility will manage business development and fund raising activities of the Company while corporate headquarters, research & development and manufacturing operations will continue in Colorado. ...
- Research articles 2005-04-19
- Vitro's cell immortalization patent allowed.(Brief Article)
- Vitro Diagnostics, Inc. (Aurora, CO; 720-859-4120) announced the receipt of a "Notice of Allowance" from the United States Patent and Trademark Office for a patent application entitled, "Immortalized Cell Lines and Methods of Making the Same." During the mid-1990's, the company developed novel technology that ...
- Research articles 2002-06-01
- Asuragen Signs Armored RNA® Licensing Agreement with Focus Diagnostics
- AUSTIN, Texas & CYPRESS, Calif. -- Asuragen, Inc., announces that it has granted Focus Diagnostics, Inc., the infectious disease diagnostics company of Quest Diagnostics, non-exclusive worldwide rights to incorporate Armored RNA([R]) technology into its in vitro molecular diagnostics products. Under the terms of the Agreement, Asuragen will develop and supply...
- Research articles 2008-09-09
- Fujirebio Diagnostics Chief Scientific Officer Named to Immunology Devices Panel Of the Medical Devices Advisory Committee; Committee Offers Independent Professional and Technical Advice to U.S. FDA
- MALVERN, Pa. -- Fujirebio Diagnostics, Inc. FDI, a world-leader in in-vitro diagnostics, today announced that its vice president and chief scientific officer, Dr. W. Jeffrey Allard, has been named as an industry representative to the Immunology Devices Panel of the Medical Devices Advisory Committee, a group of outside experts that...
- Research articles 2006-05-02
- Analysis Leads Roche Diagnostics to Select FalconStor's VirtualTape Library for Rapid Backup and Restore Capabilities; VTL Appliance Simplifies Backup of 85 Terabytes of Storage for Healthcare Group Division
- MANNHEIM, Germany -- FalconStor Software, Inc. (Nasdaq: FALC), a leading developer of network storage software solutions, today announced that Roche Diagnostics GmbH in Mannheim, a world leader in in-vitro diagnostics, has chosen FalconStor's VirtualTape Library VTL solution to simplify and accelerate backup and restore operations for a 2 Gigabit Fibre...
- Research articles 2005-03-08
- QIAGEN expands its portfolio of licenses to real-time PCR.(real-time polymerase chain reaction agreement with Roche Biomedical Laboratories Inc.)
- QIAGEN N.V. (Venlo, The Netherlands), the worldwide leading provider of sample and assay technologies for research in life sciences, applied testing and molecular diagnostics announced that it has acquired licenses from Roche, as well as from Ortho Clinical Diagnostics. These two license agreements significantly expand QIAGEN's...
- Research articles 2007-04-01
- First Medical, Inc. Gains Exclusive Rights to Heart Failure Diagnostic Markers; Collaborative Agreement to Focus on Development of New Diagnostic and Therapeutic Markers
- MOUNTAIN VIEW, Calif.--BUSINESS WIRE--Dec. 12, 1994--First Medical, Inc., an in vitro diagnostics company, Monday announced a collaborative agreement with the University of Colorado Health Sciences Center's Division of Cardiology covering research and development of heart failure diagnostics and therapeutics. Under terms of the agreement, First Medical will...
- Research articles 1994-12-12
- Ambion, Inc - Brief Article
- Ambion, Inc. has granted Abbott Laboratories nonexclusive rights to use Ambion's Armored RNA technology in products and processes for in vitro diagnostics. Under the terms of the agreement, Abbott can manufacture Armored RNA controls and standards for Use in its diagnostic kits. Armored RNA technology was developed by Ambion...
- Research articles 2000-07-01
- Ambion, Inc - Brief Article
- Ambion, Inc. has granted Abbott Laboratories nonexclusive rights to use Ambion's Armored RNA technology in products and processes for in vitro diagnostics. Under the terms of the agreement, Abbott can manufacture Armored RNA controls and standards for use in its diagnostic kits. Armored RNA technology was developed by Ambion and...
- Research articles 2000-06-01
- Fujirebio Buys Centocor's Diagnostics Division.
- CENTOCOR INC . will sell its oncology diagnostics business to Fujirebio Inc. of Japan for nearly $37.5 million. The acquisition covers Centocor's in vitro diagnostic operations, which include immunoassays using monoclonal anti body technology. Revenues for Centocor's diagnostics business were $35.4 million in 1997. ...
- Research articles 1998-11-09
- Biomira Receives Fda Expedited Review Status For Breast Cancer Diagnostic Blood Test Kit
- EDMONTON, Alberta--BUSINESS WIRE--April 21, 1995--Biomira Inc. today announced that Biomira Diagnostics Inc., Toronto, its wholly-owned subsidiary, has been advised by the U.S. Food and Drug Administration FDA that the FDA has accepted as suitable for filing the Premarket Approval Application PMA of Biomira Diagnostics for its TRUQUANTR BRTM radioimmuno-assay RIA...
- Research articles 1995-04-20
- Epigenomics AG and Affymetrix Announce Strategic Diagnostics Platform Agreement
- BERLIN & SEATTLE, & SANTA CLARA, Calif. -- Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, and Affymetrix Inc. (NASDAQ:AFFX) announced today that Affymetrix has granted Epigenomics non-exclusive access to Affymetrix microarray technology to develop and market microarray-based in-vitro diagnostic IVD tests...
- Research articles 2006-06-27
- IRIS Awarded Gold Vendor Designation by MedAssets Supply Chain Systems
- CHATSWORTH, Calif. -- Iris Diagnostics, a division of IRIS INTERNATIONAL, INC. (NASDAQ: IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that it has earned MedAssets Supply Chain Systems Gold Vendor Award, one of the highest vendor designations...
- Research articles 2008-06-02
- AccuMed, Inc. and Alamar Biosciences, Inc. enter into a definitive agreement
- CHICAGO--BUSINESS WIRE--April 24, 1995-- ACCUMED, INC., a privately-held company and provider of laboratory diagnostics, and Alamar Biosciences, Inc. (NASDAQ: ALMR), a manufacturer and marketer of in vitro diagnostic testing products, jointly announced today they have entered into a definitive agreement to merge. The companies previously announced the intent to...
- Research articles 1995-04-24
- Affymetrix and PathWork Informatics Forge Collaboration to Develop New Cancer Diagnostics
- SANTA CLARA, Calif. & SAN JOSE, Calif. -- Affymetrix Inc. (Nasdaq:AFFX) and PathWork Informatics Inc. announced today that Affymetrix has granted PathWork long-term non-exclusive access to its microarray technology to develop and market in-vitro diagnostic tests for cancer. Under the agreement, PathWork has the right to use Affymetrix microarray technology...
- Research articles 2005-11-01
- Adaltis Inc. Provides Update on its Activities and Financing Requirements
- Adaltis Inc. (TSX: ADS), an international in vitro diagnostic IVD company wishes to communicate recent changes in its key leadership team and recent developments in its business prospects. The Corporation previously announced in February 2009 the appointment of Mr. Peter Bambic as President and Chief Executive Officer...
- Research articles 2009-04-29
- Adaltis Inc. Provides Update on its Activities and Financing Requirements.
- MONTREAL, QUEBEC, Apr 29, 2009 Marketwire via COMTEX -- Adaltis Inc. (TSX:ADS), an international in vitro diagnostic IVD company wishes to communicate recent changes in its key leadership team and recent developments in its business prospects. The Corporation previously announced in February...
- Research articles 2009-04-29
- Renovar Presents Data on New Kidney Diagnostic at American Transplantation Congress
- MADISON, Wis. -- Renovar, Inc., an in vitro diagnostics company, announced results of its new test for kidney transplant patients, at the American Transplantation Congress in Seattle, Washington. The meeting is the Joint Annual Meeting of the American Societies of Transplant Surgeons and Transplantation.
- Research articles 2005-05-25
- << Previous
- page 1 of 2
- Next >>
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
